Loading clinical trials...
Loading clinical trials...
A Multicenter, Pivotal Phase 3 Study of Iomab-B Prior to Allogeneic Hematopoietic Cell Transplant Versus Conventional Care in Older Subjects With Active, Relapsed or Refractory Acute Myeloid Leukemia (AML)
Conditions
Interventions
Iomab-B
Conventional Care
+1 more
Locations
24
United States
Banner MD Anderson Cancer Center
Gilbert, Arizona, United States
Yale Cancer Center
New Haven, Connecticut, United States
Georgetown University Medical Center
Washington D.C., District of Columbia, United States
Mayo Clinic
Jacksonville, Florida, United States
Loyola University Medical Center
Maywood, Illinois, United States
University of Iowa
Iowa City, Iowa, United States
Start Date
June 1, 2016
Primary Completion Date
June 1, 2022
Completion Date
December 1, 2026
Last Updated
July 19, 2023
NCT05564390
NCT03050268
NCT07320235
NCT06439199
NCT06782542
NCT05886049
Lead Sponsor
Actinium Pharmaceuticals
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions